PHVS
Pharvaris NV
Pharmaceuticals
Pharvaris NV (PHVS) Stock News
The latest PHVS headlines and market coverage — 1 recent story, updated throughout the day.
- The Motley Fool·Neutral
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
Pharvaris director Johannes Schikan sold 37,600 shares worth $1.3 million in late June 2026, representing 10.66% of his direct holdings. The sale occurred under a Rule 10b5-1 trading plan following a 96.5% one-year stock price appreciation. Shortly after, the FDA accepted the company's New Drug Application for its lead drug deucrictibant for hereditary angioedema treatment, though the stock has remained relatively flat since the announcement.